In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vibha Ravi

Senior Editor

India

Vibha provides news and analysis for Pink Sheet and Scrip on a broad range of subjects related to companies, including deals, strategy, regulation and policy. Her multimedia content including infographics and podcasts have helped her win internal awards. She brings her education in business management and experience as a senior journalist for AFX-Asia to bear in spotting trends. As an attendee and panelist at conferences, she strives to bring unique insights to the audience. In her spare time, she enjoys travel, photography and blogging.

Latest From Vibha Ravi

Merck As Anchor, Scale As Lever, Aurobindo Looks To Spar With Lonza, WuXi Group

Starting off with MSD as an anchor partner, Aurobindo plans to eventually spar with the likes of WuXi and Lonza while building scale for its biologics CDMO business. Meanwhile, EMA approval for a greenfield project in China and an US FDA nod for Ryzneuta, licensed from Yifan’s Evive Biotech, signal a boost.

Strategy Sales & Earnings

Merck As Anchor, Scale As Lever, Aurobindo Looks To Spar With Lonza, WuXi Group

Starting off with MSD as an anchor partner, Aurobindo plans to eventually spar with the likes of WuXi and Lonza while building scale for its biologics CDMO business. Meanwhile, EMA approval for a greenfield project in China and an US FDA nod for Ryzneuta, licensed from Yifan’s Evive Biotech, signal a boost

Business Strategies Commercial

Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug

Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.

Deal Watch Business Strategies

Generic Spiriva Delivers First Mover Advantage In US, Lupin Plans Europe Launch

Lupin’s Q2 margins jumped post launch of the first Spiriva generic in the US, encouraging launch plans for Europe and Canada. With four out of five plants clearing a regulatory overhang from earlier warning letters, the specialty engine is revving up though competition in first-to-file products launched earlier could dampen margins somewhat.

Strategy Generic Drugs

gSpiriva Delivers First Mover Advantage In US, Lupin Plans Europe Launch

Lupin’s Q2 margins jumped post launch of the first Spiriva generic in the US, encouraging launch plans for Europe and Canada. With four out of five plants clearing a regulatory overhang from earlier warning letters, the specialty engine is revving up though competition in first-to-file products launched earlier could dampen margins somewhat

Commercial Business Strategies

Zydus On Acquisitions, $100m Specialty Biz Target, Asacol Competition

Zydus is still on the lookout for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of generic Revlimid sales in Q2 led to a 24% drop over the previous quarter.

Sales & Earnings Strategy
See All
UsernamePublicRestriction

Register